Clinicopathological and prognostic significance of phosphorylated PRAS40 (Thr246) in breast cancer

Asian Biomedicine

Volumn 6, Issue 4, 2012, Pages 573-577

  Fu, Rongzhan ^a   Wu, Hongyan ^a   Yuan, Kai ^a   Zhang, Kun ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Biomarker; Phosphorylation; PI3K pathway; PRAS40; Targeted therapy

Indexed keywords

PRAS40 PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; DISEASE SEVERITY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SURVIVAL RATE;

EID: 84871678763     PISSN: 19057415     EISSN: 1875855X     Source Type: Journal    
DOI: 10.5372/1905-7415.0604.092     Document Type: Article

References (8)

1. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, el al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004; 304:554. (Pubitemid 38541907)
2. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009; 9:550-62.
3. Hernandez-Aya LF, Gonzalez-Angulo AM. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist. 2011; 16:404-14.
4. Andersen JN, Sathyanarayanan S, Di Bacco A, Chi A, Zhang T, Chen AH, et al. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Sci Transl Med. 2010; 2:43ra55.
5. Bedard PL, Cardoso F, Piccart-Gebhart MJ. Stemming resistance to HER-2 targeted therapy. J Mammary Gland Biol Neoplasia. 2009; 14:55-66.
6. Kolasa IK, Rembiszewska A, Felisiak A, Ziolkowska-Seta I, Murawska M, Moes J, et al. PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients. Cancer Biol Ther. 2009; 8:21-6.
7. Coughlin CM, Johnston DS, Strahs A, Burczynski ME, Bacus S, Hill J, et al. Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy. Breast Cancer Res Treat. 2010; 124:1-11.
8. Moulder SL.Does the PI3K pathway play a role in basal breast cancer? Clin Breast Cancer. 2010; 10 Suppl 3:S66-71.